A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton
- 3 May 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 7 (5) , 705-712
Abstract
Fibrodysplasia ossificans progressiva (FOP) is a disabling genetic condition that leads to the formation of a second (heterotopic) skeleton, and is the most catastrophic disorder of heterotopic ossification in humans. Throughout childhood and early adult life, FOP progressively immobilizes all of the joints of the normotopic skeleton, rendering movement impossible. At present, there is no effective prevention or treatment. Recently, a recurrent mutation in the glycine-serine activation domain of the activin receptor IA/activin-like kinase-2, a bone morphogenetic protein type I receptor, was reported in all sporadic and familial cases of classic FOP, making this one of the most highly specific disease-causing mutations in the human genome. The discovery of the FOP gene establishes a critical milestone in understanding FOP, reveals a highly conserved druggable target in the TGF-β/bone morphogenetic protein signaling pathway and compels therapeutic approaches for the development of small molecule signal tran...Keywords
This publication has 45 references indexed in Scilit:
- Treatment Considerations for the Management of Fibrodysplasia Ossificans ProgressivaClinical & Translational Metabolism, 2005
- The Genetics of Fibrodysplasia Ossificans ProgressivaClinical & Translational Metabolism, 2005
- The Fibrodysplasia Ossificans Progressiva LesionClinical & Translational Metabolism, 2005
- Immunological Features of Fibrodysplasia Ossificans Progressiva and the Dysregulated BMP4 PathwayClinical & Translational Metabolism, 2005
- The Phenotype of Fibrodysplasia Ossificans ProgressivaClinical & Translational Metabolism, 2005
- Mast cell involvement in fibrodysplasia ossificans progressivaHuman Pathology, 2001
- Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressivaOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 1996
- Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressivaThe Journal of Pediatrics, 1995
- The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients.Journal of Bone and Joint Surgery, 1993
- The histopathology of fibrodysplasia ossificans progressiva. An endochondral process.Journal of Bone and Joint Surgery, 1993